Safety and Efficacy Evaluation of LC-K76 in Patients With Metastatic Hormone-Sensitive Prostate Cancer

Official title

An Open-Label, Exploratory Study to Evaluate the Safety and Preliminary Efficacy of LC-K76 in Combination With Endocrine Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer

Overview

This study is a single-centre, randomised, paired 24-week intervention dosing trial. Its purpose is to evaluate the safety profile and efficacy of the investigational drug in subjects with metastatic hormone-sensitive prostate cancer receiving oral LC-K76 treatment. Following a screening period not exceeding three weeks, subjects will enter a one- to two-week matching and randomization phase. Subsequently, subjects will be assigned to receive the study drug for a 24-week treatment period, followed by a 24-week follow-up period.

Interventions

• Drug Standard Endocrine Therapy
  Participants in this arm receive the standard-of-care endocrine therapy for metastatic hormone-sensitive prostate cancer (mHSPC). This regimen consists of Androgen Deprivation Therapy (ADT) (e.g., Goserelin, Leuprorelin, Triptorelin, or Degarelix) combined with an oral Androgen Receptor (AR) inhibitor (e.g., Apalutamide, Enzalutamide, Darolutamide, Rezvilutamide, or Abiraterone Acetate). The specific choice of drugs is determined by the investigator based on approved clinical use .
• Dietary supplement LC-K76
  Oral administration at a dose of 1.2 g twice daily (BID), taken 30 minutes before breakfast and dinner, for a treatment period of 24 weeks.

Primary outcome measures

• Incidence of Adverse Events (AEs) [Time frame: From baseline to primary completion, which may take up to 24 to 48 weeks]

Secondary outcome measures (5)

• PSA Undetectable Rate [Time frame: From baseline to primary completion, which may take up to 24 to 48 weeks]
• PSA Response Rate [Time frame: From baseline to primary completion, which may take up to 24 to 48 weeks]
• Time to CRPC（Castration-Resistant Prostate Cancer） [Time frame: From baseline to primary completion, which may take up to 24 to 48 weeks]
• Disease Control Rate (DCR) [Time frame: From baseline to primary completion, which may take up to 24 to 48 weeks]
• Radiographic Progression-Free Survival （rPFS ） [Time frame: From baseline to primary completion, which may take up to 24 to 48 weeks]

Eligibility criteria

Inclusion criteria

• Male, aged ≥ 18 years.
• Histologically or cytologically confirmed newly diagnosed metastatic hormone-sensitive prostate adenocarcinoma, without small cell carcinoma or small cell components.
• Presence of at least one bone metastasis or visceral metastasis (excluding lymph nodes) detected by systemic imaging (CT/MRI).
• No prior treatment for prostate cancer before enrollment (including but not limited to radical surgery, radiotherapy, endocrine therapy, or chemotherapy).
• No history of allergy to dandelion or dandelion products.
• ECOG performance status ≤ 2.
• Plan to receive and maintain Androgen Deprivation Therapy (ADT) combined with an androgen receptor antagonist (e.g., enzalutamide, apalutamide, darolutamide), abiraterone acetate, or other drugs inhibiting testosterone synthesis during the study period.
• Subjects are able to comply with oral LC-K76 capsule administration and adhere to study requirements throughout the study

Exclusion criteria

• Lack of pathological evidence for prostate cancer diagnosis.
• Prior receipt of any treatment modality for prostate cancer.
• Patients with other primary malignant tumors that were progressive or required active treatment within the past 3 years.
• Patients with diabetes requiring continuous insulin therapy or poorly controlled diabetes.
• Known or suspected central nervous system metastases or active leptomeningeal disease.
• Significant abnormalities in bone marrow, coagulation, renal, and hepatic function, defined as laboratory values at randomization: Hemoglobin < 90 g/L, Neutrophils < 1.5 × 10$\^9$/L, Platelets < 75 × 10$\^9$/L, ALT > 2.5 × ULN, AST > 2.5 × ULN, or Serum Total Bilirubin > 1.5 × ULN; eGFR < 60 mL/min/1.73m$\^2$.
• Any severe disease affecting cardiopulmonary function or high-risk conditions.
• History of severe drug allergies.
• Presence of factors interfering with swallowing, chronic diarrhea, intestinal obstruction, or other factors affecting drug intake and absorption.
• Concurrent psychiatric illness or neurological symptoms judged to make participation difficult.
• Any condition that, in the judgment of the investigator, poses a severe safety risk to the patient, may confound study results, or may affect the patient's ability to complete the study (e.g., poorly controlled hypertension, severe diabetes, neurological or psychiatric disorders), or any other relevant conditions.
• Concurrent participation in other clinical trials or use of other investigational drugs.
• Refusal or inability to sign the informed consent form.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

Randomized

Model

Parallel assignment

Masking

Open label

Primary purpose

Treatment

Study locations

China · 1 center

• Changzheng hospital — Shanghai

Identifiers

NCT: NCT07389174 · LC-K76-101

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗